Lv12
60 积分 2026-07-15 加入
First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study
2小时前
已完结
Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)
2小时前
已完结
Reassessing the Incidence and Risk Factors of Radiation Pneumonitis in Treatment-Naive EGFR-Mutant NSCLC With Concurrent Third-Generation EGFR-TKI and Thoracic Radiotherapy
2小时前
已完结
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)
3小时前
已完结
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?
4小时前
已完结
Linking tumour angiogenesis and tumour immunity
3个月前
已完结
Gender Differences Regarding Palliative Care Consultation Among Persons Hospitalized With Heart Failure
皖公网安备34019202002308
